The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

KarXT combines xanomeline, a novel muscarinic M1/M4 agonist, with trospium, an already-approved muscarinic antagonist designed to reduce M1/M4-related side effects in the peripheral nervous system.